Publication | Closed Access

LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Lba36 NivolumabNeoadjuvant TherapyMedicinePathologyImmune Checkpoint InhibitorCheckmate 651Molecular OncologyHead And Neck CancerCancer TreatmentNeck OncologyOncologyRadiation OncologyCancer ResearchFinal Results